Your browser version is outdated. We recommend that you update your browser to the latest version.

Our Approach to efficient Cancer Immunotherapy

It is expected that a major advancement in future cancer treatment will be based on combining existing and novel treatment regimens to improve survival.

The MonTa Biosciences' technology is a promising technology to combine with existing types of cancer treatment, by boosting the immune system with nanoparticles carrying TLR agonists that targets immune cells in the blood. The immune cells are activated to enhance tumor cell uptake and build an anti-tumor memory response that is able to mount a response towards primary as well as metastasis in the patient, aiming to cure pateitns with metastatic disease. 

Some of the most promising combination treatments with our technology includes: 

Combination with Radiotherapy

Radiotherapy is applied to 50 % of cancer patients at some stage of their treatment. Radiotherapy cause tumor cell death in the irradiated tumor. The dead tumor cells are cleared by the immune system, and in some cases activate the immune system to fight other tumors in the patient including metastasis (abscopal effect). It is well known that monocytes and other phagocytes play a major role for this effect, but also that these cell types are less active in cancer patients than in healthy individuals.

Our strategy is to boost the activation of monocytes in the cancer patients post radiotherapy to promote the abscopal effect, leading to education of the immune system to recognize, fight and eliminate metastasis in the patient.

Combination with Therapeutic Antibodies

Therapeutic Antibodies like Avastin®, Rituximab®, Erbitux® and Herceptin® cause tumor and stroma cell death. This effect is partly mediated through the Antibody Dependent Cell Cytotoxic effect (ADCC) and Antibody Dependent Cell Phagocytic effect (ADCP). ADCC and ADCP are mediated by phagocytic cells like monocytes, and this effect is less active in cancer patients compared to healthy individuals.

Our strategy is to enhance the ADCC and ADCP effects in cancer patients after treatment with therapeutic antibodies followed by MonTa Immune stimulating liposomes. 

Combination with Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors like Ipilimumab® target the immune escape mechanism to promote survival of cancer patients with e.g. metastatic melanoma.

Our strategy is to combine MonTa Immune stimulating liposomes with Immune Checkpoint inhibitors to promote tumor elimination through immune activation together with suppression of immune escape.